☆ 4.8 Editorial Material

SnapShot: Hepatocellular Carcinoma

CANCER CELL (2014)

期刊

CANCER CELL

卷 25, 期 4, 页码 550-550

出版社

CELL PRESS

DOI: 10.1016/j.ccr.2014.04.002

关键词

-

类别

Oncology Cell Biology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Pharmacology & Pharmacy

Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress

Zachary J. Brown, D. Brock Hewitt, Timothy M. Pawlik

Summary: Unfortunately, some HCC patients are not eligible for curative treatments, making locoregional treatments like TACE crucial. Systemic therapy has advanced in the past decade, with combination atezolizumab and bevacizumab now the standard for advanced disease. Combination therapies with TACE, including systemic therapies, locoregional therapies, and immunotherapies, show promise for the management of intermediate stage HCC.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Epidemiology of Hepatocellular Carcinoma

Katherine A. McGlynn, Jessica L. Petrick, Hashem B. El-Serag

Summary: Liver cancer, particularly hepatocellular carcinoma (HCC), is a major global health concern. While HBV and HCV remain important risk factors for HCC, efforts in vaccination and treatment are showing promise. However, the increasing prevalence of metabolic risk factors like obesity and diabetes, as well as other factors like excessive alcohol consumption, present ongoing challenges in the prevention of liver cancer.

HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Combined hepatocellular-cholangiocarcinoma: An update

Maria Reig, Giuseppe Cabibbo

Summary: The potential impact of DAAs in BCLC-B/C stage patients with HCC is understudied, as HCC patients have been excluded from DAA trials. The decision on using DAAs should be made based on individual patient profiles.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Combined hepatocellular-cholangiocarcinoma: An update

Aurelie Beaufrere, Julien Calderaro, Valerie Paradis

Summary: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a tumor with both hepatocytic and biliary differentiation, whose diagnosis is primarily based on morphology and immunostaining, with a prognosis worse than hepatocellular carcinoma and treatment limited to surgery.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Combination immunotherapy for hepatocellular carcinoma

Lorenza Rimassa, Richard S. Finn, Bruno Sangro

Summary: Single-agent immune checkpoint inhibitors (ICIs) have limited efficacy in advanced hepatocellular carcinoma (HCC) patients, and approximately 30% of patients show intrinsic resistance to ICIs. Therefore, researchers are exploring combination therapies, such as anti-angiogenic agents and other ICIs. Some trials have shown promising results and potential for clinical application. However, there are still many unanswered questions that require further research.

JOURNAL OF HEPATOLOGY (2023)

添加到收藏夹

Review Oncology

Sarcomatoid hepatocellular carcinoma versus conventional hepatocellular carcinoma: a systematic review and meta-analysis

Tian-Run Lv, Hai-Jie Hu, Parbatraj Regmi, Fei Liu, Fu-Yu Li

Summary: Sarcomatoid hepatocellular carcinoma (SHCC) is a rare subtype of primary liver malignancies. Compared to conventional hepatocellular carcinoma (HCC), SHCC has worse prognosis and exhibits more aggressive behavior.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Epigenetics in hepatocellular carcinoma

Ganji Purnachandra Nagaraju, Begum Dariya, Prameswari Kasa, Sujatha Peela, Sujatha Peela Bassel F. El-Rayes

Summary: HCC is the most common primary malignancy of the liver, with a high fatality rate. Genetic and epigenetic aberrations are commonly observed in HCC, including chromatin remodeling, histone alterations, DNA methylation, and ncRNA expression. In-depth understanding of the epigenetics of HCC is critical for developing rational clinical strategies, improving overall survival, and predicting therapeutic outcomes.

SEMINARS IN CANCER BIOLOGY (2022)

添加到收藏夹

Review Medicine, Research & Experimental

Hepatocellular Carcinoma Immunotherapy

Rubens Copia Sperandio, Roberto Carmagnani Pestana, Beatriz Viesser Miyamura, Ahmed O. Kaseb

Summary: Hepatocellular carcinoma (HCC) is a common primary liver malignancy and a leading cause of cancer-related death. Single-agent anti-PD-1 immune checkpoint inhibitors (ICIs) showed initial promise, but failed to demonstrate efficacy in phase III trials. The combination of atezolizumab and bevacizumab has been approved as first-line therapy, showing significant improvements in response rate, progression-free survival, and overall survival compared to standard treatments. Ongoing clinical trials are evaluating the use of ICIs in combination with other drugs.

ANNUAL REVIEW OF MEDICINE (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Partial EMT in Squamous Cell Carcinoma: A Snapshot

Chengcheng Liao, Qian Wang, Jiaxing An, Qian Long, Hui Wang, Meiling Xiang, Mingli Xiang, Yujie Zhao, Yulin Liu, Jianguo Liu, Xiaoyan Guan

Summary: Partial EMT is a plastic state in cancer cells where both epithelial and mesenchymal characteristics are exhibited, regulated by various pathways and molecules, leading to aggressive tumorigenic properties and high stemness, resulting in therapy resistance and metastasis.

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2021)

添加到收藏夹

Review Medicine, Research & Experimental

β-Catenin signaling in hepatocellular carcinoma

Chuanrui Xu, Zhong Xu, Yi Zhang, Matthias Evert, Diego F. Calvisi, Xin Chen

Summary: Deregulated Wnt/β-catenin signaling is a major genetic alteration in hepatocellular carcinoma (HCC), and its activation plays an oncogenic role in hepatocarcinogenesis. The activated pathway is associated with specific gene expression patterns and pathological features, and it synergizes with other signaling cascades to promote HCC formation. Therefore, understanding and targeting this pathway has important implications for the diagnosis, classification, and personalized treatment of HCC.

JOURNAL OF CLINICAL INVESTIGATION (2022)

添加到收藏夹

Review Oncology

Exosomal microRNAs in hepatocellular carcinoma

Chenbin Liu, Han Wu, Yinqi Mao, Wei Chen, Shuying Chen

Summary: Exosomal microRNAs play a crucial role in hepatocellular carcinoma, holding significant value in the early diagnosis and treatment of this disease.

CANCER CELL INTERNATIONAL (2021)

添加到收藏夹

Review Immunology

H-TEX-mediated signaling between hepatocellular carcinoma cells and macrophages and exosome-targeted therapy for hepatocellular carcinoma

Sihang Yu, Lei Zhou, Jiaying Fu, Long Xu, Buhan Liu, Yuanxin Zhao, Jian Wang, Xiaoyu Yan, Jing Su

Summary: There is increasing evidence showing the crucial role of the immune microenvironment, particularly the polarization state and function of macrophages, in the development of hepatocellular carcinoma. Tumor-derived exosomes in hepatocellular carcinoma act as information carriers and regulate the physiological state of cells in the microenvironment, thus controlling cancer progression. This review focuses on the role of exosome content in disease outcomes at different stages of hepatitis B virus/hepatitis C virus-induced hepatocellular carcinoma, and explores the mechanism by which macrophages contribute to hepatocellular carcinoma formation and the regulation of macrophage functions by the heterogeneity of exosome loading. The application prospects of exosome-based targeted drug delivery in immunotherapy research on hepatocellular carcinoma are also summarized.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Review Medicine, Research & Experimental

Immunotherapy for hepatocellular carcinoma

Mingzhen Zhou, Baorui Liu, Jie Shen

Summary: Hepatocellular carcinoma (HCC) is a common malignancy with late-appearing symptoms, making diagnosis and treatment challenging. Immunotherapy, including immune checkpoint inhibitors, liver cancer vaccines, and cellular therapies, has emerged as a new hope for HCC treatment by regulating the immune system to target liver cancer cells.

CLINICAL AND EXPERIMENTAL MEDICINE (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Global Epidemiology and Genetics of Hepatocellular Carcinoma

Ming Ren Toh, Evelyn Yi Ting Wong, Sunny Hei Wong, Alvin Wei Tian Ng, Lit-Hsin Loo, Pierce Kah-Hoe Chow, Joanne Ngeow

Summary: Hepatocellular carcinoma (HCC) is a leading global cancer, primarily occurring in genetically susceptible individuals with liver cirrhosis and exposure to risk factors. Temporal and geographical variations exist in HCC, with a shift from viral to nonviral causes and a higher burden in regions with a high sociodemographic index. Hepatitis viruses are the predominant causes of HCC in Asia and Africa, while genetic conditions contributing to HCC risk are less recognized outside North America and Europe. This review evaluates the epidemiology, risk factors, and genetics of HCC, including monogenic diseases, single-nucleotide polymorphisms, gut microbiome, and somatic mutations.

GASTROENTEROLOGY (2023)

添加到收藏夹

Review Oncology

Recent therapeutics in hepatocellular carcinoma

Zhe Fan, Pengcheng Zhou, Binghui Jin, Guangyao Li, Lu Feng, Chengjun Zhuang, Shuang Wang

Summary: Hepatocellular carcinoma is a malignant tumor of hepatocytes that often has hidden presentation and rapid progression. Early stage HCC has no obvious symptoms and is usually diagnosed at an advanced stage, making it difficult to treat with only supportive and symptomatic treatment. Recent advancements in medical technology have led to the development of comprehensive treatment methods based on surgery.

AMERICAN JOURNAL OF CANCER RESEARCH (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients

C. Labenz, J. S. Baron, G. Toenges, J. M. Schattenberg, M. Nagel, M. F. Sprinzl, M. Nguyen-Tat, T. Zimmermann, Y. Huber, J. U. Marquardt, P. R. Galle, M. -A. Woerns

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)

添加到收藏夹

Article Medicine, General & Internal

Recipient liver function before liver transplantation influences post-transplantation survival in patients with HCC

Friedrich Foerster, Jens Mittler, Felix Darstein, Michael Heise, Jens U. Marquardt, Marcus-Alexander Woerns, Arndt Weinmann, Lina Saelter, Maria Hoppe-Lotichius, Stefan Heinrich, Roman Kloeckner, Michael B. Pitton, Joern M. Schattenberg, Martin F. Sprinzl, Christoph Dueber, Gerd Otto, Hauke Lang, Peter R. Galle, Tim Zimmermann

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2018)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

The Role of Transforming Growth Factor-beta in Human Hepatocarcinogenesis: Mechanistic and Therapeutic Implications From an Integrative Multiomics Approach

Jens Marquardt

GASTROENTEROLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Cytoplasmic localization of the cell polarity factor scribble supports liver tumor formation and tumor cell invasiveness

Shan Wan, Anne-Sophie Meyer, Sofia Maria Elisabeth Weiler, Christian Rupp, Marcell Toth, Carsten Sticht, Stephan Singer, Stefan Thomann, Stephanie Roessler, Marina Schorpp-Kistner, Jennifer Schmitt, Norbert Gretz, Peter Angel, Darjus Felix Tschaharganeh, Jens Marquardt, Peter Schirmacher, Federico Pinna, Kai Breuhahn

HEPATOLOGY (2018)

添加到收藏夹

Article Cell Biology

Recombinant human hepatocyte growth factor provides protective effects in cerulein-induced acute pancreatitis in mice

Mayrel Palestino-Dominguez, Mario Pelaez-Luna, Roberto Lazzarini-Lechuga, Ignacio Rodriguez-Ochoa, Veronica Souza, Roxana U. Miranda, Benjamin Perez-Aguilar, Leticia Bucio, Jens U. Marquardt, Luis Enrique Gomez-Quiroz, Maria Concepcion Gutierrez-Ruiz

JOURNAL OF CELLULAR PHYSIOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

The role of molecular enrichment on future therapies in hepatocellular carcinoma

Jean-Charles Nault, Peter R. Galle, Jens U. Marquardt

JOURNAL OF HEPATOLOGY (2018)

添加到收藏夹

Article Oncology

Update on systemic therapy of advanced hepatocellular carcinoma

Jens U. Marquardt, Arndt Vogel

ONKOLOGE (2018)

添加到收藏夹

Article Medicine, General & Internal

Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy

Christian Labenz, Larissa Beul, Gerrit Toenges, Joern M. Schattenberg, Michael Nagel, Martin F. Sprinzl, Marc Nguyen-Tat, Tim Zimmermann, Yvonne Huber, Jens U. Marquardt, Peter R. Galle, Marcus-Alexander Woerns

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2019)

添加到收藏夹

Article Cell Biology

Cholesterol burden in the liver induces mitochondrial dynamic changes and resistance to apoptosis

Mayra Dominguez-Perez, Arturo Simoni-Nieves, Patricia Rosales, Natalia Nuno-Lambarri, Monica Rosas-Lemus, Veronica Souza, Roxana U. Miranda, Leticia Bucio, Salvador Uribe Carvajal, Jens U. Marquardt, Daekwan Seo, Luis E. Gomez-Quiroz, Maria Concepcion Gutierrez-Ruiz

JOURNAL OF CELLULAR PHYSIOLOGY (2019)

添加到收藏夹

Article Oncology

Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma

Martin F. Sprinzl, Martha M. Kirstein, Sandra Koch, Marie-Luise Seib, Julia Weinmann-Menke, Hauke Lang, Christoph Dueber, Gerrit Toenges, Daniela Zoeller, Jens U. Marquardt, Marcus-Alexander Woerns, Peter R. Galle, Arndt Vogel, Matthias Pinter, Arndt Weinmann

LIVER CANCER (2019)

添加到收藏夹

Review Medicine, General & Internal

Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma

Carolin Czauderna, Martha M. Kirstein, Hauke C. Tews, Arndt Vogel, Jens U. Marquardt

Summary: Cholangiocarcinomas (CCAs) are a highly heterogeneous group of liver tumors with distinct prognostic and therapeutic traits. Specific treatment modalities are required for different subclasses, depending on anatomical localization and disease stage, to improve patient outcomes. Comprehensive molecular characterization has paved the way for precision oncological approaches in the treatment of CCAs.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

CD44 Contributes to the Regulation of MDR1 Protein and Doxorubicin Chemoresistance in Osteosarcoma

Monserrat Gerardo-Ramirez, Friederike L. Keggenhoff, Vanessa Giam, Diana Becker, Marco Groth, Nils Hartmann, Beate K. Straub, Helen Morrison, Peter R. Galle, Jens U. Marquardt, Peter Herrlich, Monika Hartmann

Summary: Osteosarcoma is the most common type of pediatric bone tumor. Research shows that CD44 plays an important role in drug resistance of osteosarcoma cells, and abnormal expression of CD44 leads to molecular alterations.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹

Article Cell Biology

Establishment and Molecular Characterization of Two Patient-Derived Pancreatic Ductal Adenocarcinoma Cell Lines as Preclinical Models for Treatment Response

Ruediger Braun, Olha Lapshyna, Jessica Watzelt, Maren Drenckhan, Axel Kuenstner, Benedikt Faerber, Ahmed Ahmed Mohammed Hael, Louisa Bolm, Kim Christin Honselmann, Bjoern Konukiewitz, Darko Castven, Malte Spielmann, Sivahari Prasad Gorantla, Hauke Busch, Jens-Uwe Marquardt, Tobias Keck, Ulrich Friedrich Wellner, Hendrik Ungefroren

Summary: The prognosis of pancreatic ductal adenocarcinoma (PDAC) is very poor, and surgical resection is the only curative treatment option. A study established two new PDAC cell lines, which exhibit distinct molecular phenotypes, providing potential models for researching new treatment strategies and developing personalized therapy regimens.

CELLS (2023)

添加到收藏夹

Article Oncology

TAp73 Inhibits EMT and Cell Migration in Pancreatic Cancer Cells through Promoting SMAD4 Expression and SMAD4-Dependent Inhibition of ERK Activation

Hendrik Ungefroren, Bjorn Konukiewitz, Rudiger Braun, Ulrich Friedrich Wellner, Hendrik Lehnert, Jens-Uwe Marquardt

Summary: Transcriptionally active p73 (TAp73) inhibits tumor progression in pancreatic ductal adenocarcinoma (PDAC) by promoting canonical TGF-beta/Smad signaling and preventing non-canonical ERK1/2-mediated TGF-beta signaling. TAp73 suppresses epithelial-mesenchymal transition and upregulates the expression of SMAD4, which mediates the inhibition of ERK activation and cell motility. Measuring the levels of TAp73 and/or SMAD4 could help predict the TGF-beta pathway preference in PDAC patients.

CANCERS (2023)

添加到收藏夹

Review Oncology

Changes in the Acetylcholinesterase Enzymatic Activity in Tumor Development and Progression

Benjamin Perez-Aguilar, Jens U. Marquardt, Encarnacion Munoz-Delgado, Rosa Maria Lopez-Duran, Maria Concepcion Gutierrez-Ruiz, Luis E. Gomez-Quiroz, Jose Luis Gomez-Olivares

Summary: The cholinergic system, specifically acetylcholine receptors (AChR) and acetylcholine (ACh), has been found to play a role in cancer development. Acetylcholinesterase (AChE), which regulates AChR by hydrolyzing ACh, has been observed to have a relevant role in cancer. However, there is controversy regarding AChE's participation in cancer, as its enzymatic activity can either increase or decrease in different tumors. This review focuses on analyzing the involvement of AChE in cancer progression and proposes AChE as a central regulator in the initiation and progression of cancer via the cholinergic system. Modulating ACh levels with AChE can regulate AChRs differentially, leading to diverse cancer events.

CANCERS (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.